Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy. Researchers analyzed data from 36 Phase I trials. The study found the overall risk to patients of suffering a life-threatening side-effect was around seven times less than for traditional cytotoxic agents.